Search Results

You are looking at 1 - 10 of 1,049 items for :

Clear All
Full access

Katy Winckworth-Prejsnar, Elizabeth A. Nardi, James McCanney, F. Marc Stewart, Terry Langbaum, Bruce J. Gould, C. Lyn Fitzgerald and Robert W. Carlson

Executive Summary Patient safety is an integral component of high-quality and effective medical care. The stakes are especially high in oncology, where avoiding errors is imperative to delivering safe and effective radiation therapy

Full access

Philip E. Johnson, George Dahlman, Kirby Eng, Rekha Garg, Scott Gottlieb, James M. Hoffman, Peyton Howell, Mohammad Jahanzeb, Shirley Johnson, Emily Mackler, Mark Rubino, Brenda Sarokhan, F. Marc Stewart, Tim Tyler, Julie M. Vose, Sharon Weinstein, Edward C. Li and Jessica DeMartino

Executive Summary Managing drug safety and developing drug safety systems is an ongoing, critically important challenge for all involved in manufacturing drugs, regulating drug use, prescribing drugs, dispensing drugs, and consuming drugs. Risk

Full access

Jennifer Hinkel

References 1. Second Annual NCCN Patient Safety Summit, Transcript. Memorial Sloan-Kettering Cancer Center, October 12 , 2006 . 2. Weingart SN Flug J Brouillard D . Oral chemotherapy safety practices at US cancer centers

Full access

Andrew D. Zelenetz, Islah Ahmed, Edward Louis Braud, James D. Cross, Nancy Davenport-Ennis, Barry D. Dickinson, Steven E. Goldberg, Scott Gottlieb, Philip E. Johnson, Gary H. Lyman, Richard Markus, Ursula A. Matulonis, Denise Reinke, Edward C. Li, Jessica DeMartino, Jonathan K. Larsen and James M. Hoffman

possible to define “highly similar” quality attributes and “no clinically meaningful differences in efficacy and safety.” The NCCN Guidelines Panels should evaluate recommendations regarding the use of biosimilars where available. This will provide

Full access

Jessica Sugalski, F. Marc Stewart and Robert W. Carlson

The mission of NCCN is to improve the quality, effectiveness, and efficiency of cancer care so that patients can live better lives. Improving medication safety is an important aspect of fulfilling this mission. In 2006, NCCN conducted a patient

Full access

Jennifer M. Hinkel

; 104 : 2289 – 2291 . 3. The Joint Commission . Facts about the 2007 National Patient Safety Goals . Available at : http://www.jointcommission.org/PatientSafety/NationalPatientSafetyGoals/07_npsg_facts.htm . Last accessed: 18 June 2008

Full access

John Glaspy

anemia frequently observed in patients with chronic illnesses, including cancer, 1 – 5 coupled with the development of parenteral iron preparations that have a more favorable safety profile than the early iron dextran products, 6 – 8 has increased

Full access

John A. Glaspy

-03) . Int J Radiat Oncol Biol Phys 2007 ; 69 : 1008 – 1017 . 22. Grote T Yeilding AL Castillo R . Efficacy and safety analysis of epoetin alfa in patients with small-cell lung cancer: a randomized, double-blind, placebo-controlled trial . J

Full access

Megan Gershon, Justine Pena, Chamnjot Bains, Sarah Salas, Tresa McGranahan and Seema Nagpal

presents significant challenges to safety of prescription, administration, and side effect monitoring. While there are guidelines for documentation, there is not a best practices system for managing OC. This project identified areas of latent errors and

Full access

Kshama Jaiswal, Madelyne Hull, Anna L. Furniss, Reina Doyle, Natalia Gayou and Elizabeth Bayliss

safety-net population with breast cancer. We examined the association between time intervals and socioeconomic factors such as language, ethnicity, and insurance. We also assessed the relationship between time intervals and patient medical factors such as